CPHI Japan 2025 | Dorra Joins Global Partners to Shape the Future of Pharmaceuticals

發(fā)布時(shí)間： 2025-04-14 閱讀：358次

分享

From April 9 to 11, the 2025 CPHI Japan was grandly held in Tokyo. Led by Chairman Mr. Shengjun Zhao, Dorra and its European office participated in the exhibition, showcasing the company’s innovative achievements and global presence in the field of pharmaceutical ingredients. During the event, Dorra engaged in in-depth exchanges with Japanese and international clients, exploring industry trends and potential opportunities for collaboration.

During the exhibition, Dorra held multiple rounds of in-depth discussions with local pharmaceutical companies, distributors, and industry experts in Japan, precisely aligning with customer needs and actively exploring opportunities for collaboration. In response to the Japanese market’s high standards for product quality and regulatory compliance, Dorra earned the trust of potential partners with its rigorous quality management system and internationally recognized certifications, laying a solid foundation for future cooperation.

With professionalism and enthusiasm, the Dorra team actively engaged with clients, keenly capturing market dynamics and effectively communicating the company’s value. Through face-to-face interactions, the team not only gained valuable market insights but also developed a clearer understanding of the specific needs of the Japanese and broader Asian markets. These insights will serve as an important reference for optimizing the company’s product pipeline and refining its market strategies.

Participating in CPHI Japan marks a significant step for Dorra in deepening its presence in the Japanese market and advancing its internationalization strategy. Looking ahead,Dorra will continue to increase investment in research and development, further optimize its global supply chain system, and strive to meet customer needs with high-quality products and services. At the same time, the company will accelerate the implementation of its international strategy, working hand in hand with global partners to shape a new and promising future for the pharmaceutical industry.